CoChat

Evidence-Based and Potential Benefits of Metformin in the Polycystic Ovary Syndrome: A Comprehensive Review

The DOI matches its Crossref record; 484 of the 491 references it cites were found in a registry or an index.

Abstract

Metformin is an insulin sensitizer widely used for the treatment of patients affected by type 2 diabetes mellitus. Because many women with polycystic ovary syndrome (PCOS) are insulin resistant, metformin was introduced in clinical practice to treat these patients also. Moreover, metformin's effect has other targets beside its insulin-sensitizing action. The present review was aimed at describing all evidence-based and potential uses of metformin in PCOS patients. In particular, we will analyze the uses of metformin not only for the treatment of all PCOS-related disturbances such as menstrual disorders, anovulatory infertility, increased abortion, or complicated pregnancy risk, hyperandrogenism, endometrial, metabolic and cardiovascular abnormalities, but also for the prevention of the syndrome.

Overview

Integrity signals

Registry

Crossref · 10.1210/er.2008-0030

Cites

484 of 484 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

4 retracted

Show all 484 references

Research works printed but not linked: 5

  1. 2005, American Association of Clinical Endocrinologists position statements on metabolic and cardiovascular consequences of polycystic ovary syndrome., Endocr Pract, 11, 126
  2. Deaton, 1991, Hyperandrogenism and uterine bleeding., Infertil Reprod Med Clin North Am, 2, 561
  3. 1992, Recent advances in medically assisted conception., WHO Tech Rep Ser, 820, 1
  4. Sonntag, 2005, Metformin alters insulin signaling and viability of human granulosa cells., Fertil Steril, 84, 1173, 10.1016/j.fertnstert.2005.04.043 · DOI
  5. Koschinsky, 1988, Influence of metformin on vascular cell proliferation., Diabetes Metab, 14, 566

Cited by

See all 426

Metadata

Authors
Palomba, S., Falbo, A., Zullo, F., & Orio, F.
Affiliations
  • Magna Graecia University (IT)
  • Parthenope University of Naples (IT)
Venue
Endocrine Reviews
Published
2008-12-04
Volume
30
Issue
1
Pages
1-50
ISSN
  • 0163-769X (ISSN-L)
  • 1945-7189
OpenAlex
W2160472557
Cited by
426
References
491
Citations by year
2026: 12 · 2025: 16 · 2024: 20 · 2023: 28 · 2022: 25 · 2021: 18 · 2020: 15 · 2019: 19 · 2018: 19 · 2017: 15 · 2016: 18 · 2015: 26 · 2014: 37 · 2013: 40 · 2012: 33
FWCI
4.00
Type
journal article
Language
en
Open access
closed
Locations
  • Endocrine Reviews (publishedVersion)
  • PubMed (publishedVersion)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
  • CINECA IRIS Institutial research information system (Parthenope University of Naples) (submittedVersion)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
Keywords
metformin, polycystic ovary syndrome, insulin sensitization, insulin resistance, menstrual disorders, anovulatory infertility, pregnancy complications, hyperandrogenism, endometrial abnormalities, cardiovascular risk, PCOS prevention, type 2 diabetes
MeSH terms
Anovulation, Cardiovascular Diseases, Endometrium, Female, Humans, Hypoglycemic Agents, Menstruation Disturbances, Metformin, Obesity, Polycystic Ovary Syndrome, Pregnancy, Pregnancy Complications, Quality of Life, Endometrial Neoplasms, Hyperandrogenism, Evidence-Based Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evidence-Based and Potential Benefits of Metformin in the Polycystic Ovary Syndrome: A Comprehensive Review. https://app.cochat.ai/papers/10.1210/er.2008-0030
The paper
Palomba, S., Falbo, A., Zullo, F., & Orio, F. (2009). Evidence-Based and Potential Benefits of Metformin in the Polycystic Ovary Syndrome: A Comprehensive Review. Endocrine Reviews. https://doi.org/10.1210/er.2008-0030

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.